Missouri legislation that would facilitate research on the therapeutic use of psilocybin mushrooms is scheduled for a public hearing today in a key Senate committee.
Senate Bill 768 was prefiled by Senator Holly Thompson Rehder in December, with the measure referred to the Senate Emerging Issues Committee on January 9. Today, the committee is scheduled to conduct a public hearing on the bill.
The measure states that “any person who acquires, uses, produces, possesses, transfers, or administers psilocybin for the person’s own therapeutic use shall not be subject to state or local criminal or civil penalties if the person” is 21 years old, has a qualifying medical condition and “has enrolled or sought to be enrolled in a clinical trial to study psilocybin to treat such conditions”.
Those wanting to do so must inform the Department of Health and Senior Services “that they plan to acquire, use, produce, possess, transfer, or administer psilocybin under this act, and they must provide the Department “with specified documentation and information”
All psilocybin must be tested in a licensed laboratory, and usage must be limited “to no more than 150 milligrams of psilocybin analyte during any 12-month period.
“A person who assists another in any of the acts permitted under this act and any laboratory testing psilocybin under this act shall not be subject to state or local criminal or civil penalties”, states the bill.
The Department “shall provide grants totaling $2 million dollars for research on the use and efficacy of psilocybin for the treatment of conditions listed in the act”, and they shall “prepare annual reports for the Governor, Lieutenant Governor, and the General Assembly on the implementation and outcomes of psilocybin use under this act.”
You can find the full text of Senate Bill 768 by clicking here.
